Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21041292 | 0.84 | GAA (0.38) | GAAALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL22713006 | 0.82 | GAA (0.50) | GAAALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL22735145 | 0.74 | KDM5B (0.34) | CYP4F2CYP4A11 | |
| SCHEMBL21041290 | 0.71 | ALDH1A1 (0.41) | GAAALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL22713059 | 0.71 | ALDH1A1 (0.41) | GAAALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL15445676 | 0.69 | GAA (0.47) | GAAALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL21152701 | 0.68 | GAA (0.51) | GAAALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL30867716 | 0.67 | GAA (0.36) | GAAALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL21002088 | 0.66 | GAA (0.49) | GAAALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL17675453 | 0.66 | GAA (0.49) | GAAALDH1A1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2021-07-01 | — | — | US | disclosed |
| US-20200377510-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2020-12-03 | — | — | US | disclosed |
| WO-2019103897-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. (US) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377510-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | SHARPIN, PIR, THPO | GAA 4378/4885ALDH1A1 421/4885CYP4F2 3255/4885 |
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | THPO, PIR, PAK6 | GAA 3618/4885ALDH1A1 228/4885CYP4F2 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.